R.H. Bluestein & Co’s Biogen BIIB Stock Holding History

R.H. Bluestein & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-705	Closed	-$244K	–	426
2021 Q2	$244K	Buy	+705	New	+$214K	0.01%	373
2020 Q3	–	Sell	-905	Closed	-$242K	–	354
2020 Q2	$242K	Sell	905 -300	-25%	-$90.2K	0.01%	276
2020 Q1	$381K	Buy	1,205 +395	+49%	+$120K	0.03%	146
2019 Q4	$240K	Buy	+810	New	+$225K	0.01%	311
2016 Q4	–	Sell	-1,000	Closed	-$313K	–	308
2016 Q3	$313K	Hold	1,000	–	–	0.02%	189
2016 Q2	$242K	Hold	1,000	–	–	0.02%	231
2016 Q1	$260K	Sell	1,000 -45	-4%	-$11.9K	0.02%	221
2015 Q4	$320K	Sell	1,045 -366	-26%	-$105K	0.02%	202
2015 Q3	$412K	Sell	1,411 -36,222	-96%	-$12M	0.03%	162
2015 Q2	$15.2M	Buy	+37,633	New	+$15.1M	0.92%	42

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

R.H. Bluestein & Co's BIIB Position: Q3 2021 in Review

R.H. Bluestein & Co sold out of Biogen (BIIB) in Q3 2021, closing a stake of 705 shares — an estimated $244K sold.

R.H. Bluestein & Co first reported a position in BIIB in Q2 2015 and held it in 10 quarters. The position peaked at $15.2M in Q2 2015. 1,039 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

R.H. Bluestein & Co reported no remaining Biogen position as of Q3 2021 after selling out during the quarter.
R.H. Bluestein & Co sold 705 Biogen shares in Q3 2021, an estimated $244K.
R.H. Bluestein & Co first reported a position in Biogen in Q2 2015 and held it in 10 quarters.
R.H. Bluestein & Co's Biogen position peaked at $15.2M in Q2 2015.
1,039 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on R.H. Bluestein & Co's 13F filing for Q3 2021, filed 12 Nov 2021.